Get started
Author

Fedor Kryukov

Observed names: F Kryukov, F. Kriukov, F. Kryukov, Fedor B. Kryukov, Fedor Kriukov, Kryukov F., Kryukov Fedor, Kryukov, Fedor, Крюков Федор Борисович, Ф.Б. Крюков
Institution: BIOCAD (Russia)
Observed institutions: University of Ostrava, Masaryk University, University Hospital Ostrava, University Hospital Brno, BIOCAD (India), BIOCAD (Russia)
ORCID: 0000-0003-0549-7274
Observed ORCIDs: 0000-0003-0549-7274, 0000-0003-4851-9277
OpenAlex ID: A5020329152
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance
2013 · L. Kubiczkova, F. Kryukov, et al. · Haematologica · 119
PDF
Plasma cell leukemia: from biology to treatment
2015 · Tomas Jelinek, Fedor Kryukov, et al. · European Journal Of Haematology · 54
PDF
Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting
2010 · Jana Cumova, L. Kovarova, et al. · International Journal of Hematology · 33
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
2013 · Elena Dementyeva, Fedor Kryukov, et al. · Journal of Translational Medicine · 28
PDF
Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
2016 · Fedor Kryukov, Pavel Nemec, et al. · Journal of Translational Medicine · 25
PDF
Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
2015 · Lenka Besse, Lenka Sedlarikova, et al. · PLoS ONE · 23
PDF
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
2010 · D. Ocadlikova, F. Kryukov, et al. · Neoplasma · 22
PDF
Nestin expression throughout multistep pathogenesis of multiple myeloma
2013 · Hana Svachova, Fedor Kryukov, et al. · British Journal of Haematology · 20
PDF
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab
2020 · Sergey M. Alexeev, Andrey V. Khorinko, et al. · BMC Cancer · 18
PDF
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity
2016 · T. Jelinek, E. Kryukova, et al. · Hematological Oncology · 15
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia
2013 · Fedor Kryukov, Elena Dementyeva, et al. · Genomics · 14
PDF
Flow cytometry in immunoglobulin light chain amyloidosis: Short review
2015 · Jana Filipova, Lucie Rihova, et al. · Leukemia Research · 13
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
2025 · K. Laktionov, A. Smolin, et al. · European Journal of Cancer · 12
Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection
2017 · Kateřina Growková, Elena Kryukova, et al. · European Journal Of Haematology · 12
PDF
High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?
2013 · Helena Paszekova, Fedor Kryukov, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
PDF
Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma
2010 · E. Dementyeva, P. Nemec, et al. · Leukemia Research · 11
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
2022 · Daniil L. Stroyakovskiy, Natalya V. Fadeeva, et al. · BMC Cancer · 10
PDF
Combination of serum microRNA‐320a and microRNA‐320b as a marker for W aldenström macroglobulinemia
2014 · Lenka Kubiczkova Besse, Lenka Sedlarikova, et al. · American Journal of Hematology · 10
PDF
Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview
2016 · Fedor Kryukov, Elena Kryukova, et al. · Gene · 9
Bone marrow plasma cell separation – validation of separation algorithm
2012 · Ivana Buresova, Jana Cumova, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 8
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
2023 · Igor V. Samoylenko, Lev V. Demidov, et al. · Journal of Modern Oncology · 7
PDF
Centrosome amplification and clonal evolution in multiple myeloma: Short review
2015 · Elena Kryukova, Fedor Kryukov, et al. · Critical Reviews in Oncology/Hematology · 7
PDF
Analysis of B-Cell Subpopulations in Monoclonal Gammopathies
2014 · Pavla Všianská, Lucie Říhová, et al. · Clinical Lymphoma Myeloma & Leukemia · 7
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
2021 · Martina Zátopková, Tereza Ševčíková, et al. · Blood Advances · 6
PDF
Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies
2017 · T Ševčíková, K Growková, et al. · Journal of Clinical Pathology · 6
PDF
Works count: 101
Citation count: 557
H-index: 12
I10-index: 18
Year
Topic
Type